BioSpace News Archive

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended June 30, 2023.

Form Bio , the breakthrough AI-powered drug discovery platform, announced today its notable achievements and product advancements for the first half of 2023.

Olink Holding AB announced its unaudited financial results for the second quarter ended June 30, 2023.

Jnana Therapeutics today announced that the first participant has been dosed in its Phase 1b clinical trial of JNT-517 in individuals with phenylketonuria (PKU). JNT-517 is a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19 and is in development as a potential first-in-class oral treatment for PKU.

Virios Therapeutics, Inc. today announced that the Food & Drug Administration (“FDA”) communicated that, following their initial review of the Company’s chronic toxicology program, the program’s studies appear adequate to support the safety of IMC-1 at the dose proposed by the Company for chronic use.

Medunik USA (member of Duchesnay Pharmaceutical Group) is pleased to announce that an increasing number of Americans with certain urea cycle disorders (UCDs) now have access to Pheburane® (sodium phenylbutyrate) through a rapidly expanding network of key pharmacy benefit managers (PBMs), state Medicaid programs or Managed Medicaid plans.

Kamada Ltd. today announced that it will release financial results for the second quarter and first half ended June 30, 2023, prior to the open of the U.S. financial markets on Wednesday, August 16, 2023.

Cullinan Oncology, Inc. today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CLN-978 for the treatment of relapsed/refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL).

Inteleos, a non-profit global healthcare certification organization, recently appointed Jasmine Rockett as director of the organization’s Point of Care Ultrasound Certification Academy.

EyePoint Pharmaceuticals, Inc. today announced that Jay S. Duker, M.D., President and Chief Executive of EyePoint Pharmaceuticals will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference.